{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:41:48Z","timestamp":1794199308938,"version":"4.8.0"},"reference-count":208,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014028","name":"H2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["668031"],"award-info":[{"award-number":["668031"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jhepr.2021.100316","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T20:44:23Z","timestamp":1622839463000},"page":"100316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":178,"title":["Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy"],"prefix":"10.1016","volume":"3","author":[{"given":"Yasuko","family":"Iwakiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100316_bib1","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib2","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","article-title":"The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule","volume":"43","author":"Iwakiri","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/gut.2007.144584","article-title":"Mechanisms of extrahepatic vasodilation in portal hypertension","volume":"57","author":"Hennenberg","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib4","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.13943.1","article-title":"Managing portal hypertension in patients with liver cirrhosis","volume":"7","author":"Sauerbruch","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.jhepr.2021.100316_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000490262","article-title":"Gut-liver Axis links portal hypertension to acute-on-chronic liver failure","volume":"34","author":"Trebicka","year":"2018","journal-title":"Visc Med"},{"key":"10.1016\/j.jhepr.2021.100316_bib6","article-title":"PREDICT identifies precipitating events associated with clinical course of acutely decompensated cirrhosis","author":"Trebicka","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-5320(70)90150-4","article-title":"An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids","volume":"31","author":"Wisse","year":"1970","journal-title":"J\u00a0Ultrastruct Res"},{"key":"10.1016\/j.jhepr.2021.100316_bib8","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/hep.1840180626","article-title":"Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow","volume":"18","author":"Bhunchet","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.1840070117","article-title":"Alcoholic liver injury: defenestration in noncirrhotic livers--a scanning electron microscopic study","volume":"7","author":"Horn","year":"1987","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1006\/bbrc.2000.4148","article-title":"VEGF can act as vascular permeability factor in the hepatic sinusoids through upregulation of porosity of endothelial cells","volume":"280","author":"Funyu","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhepr.2021.100316_bib11","doi-asserted-by":"crossref","first-page":"G757","DOI":"10.1152\/ajpgi.00017.2004","article-title":"Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation","volume":"287","author":"DeLeve","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021478","article-title":"A\u00a0transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations","volume":"6","author":"May","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100316_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/hep.1840150603","article-title":"Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver","volume":"15","author":"McGuire","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib14","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbamcr.2019.06.011","article-title":"Delta-like ligand 4\/DLL4 regulates the capillarization of liver sinusoidal endothelial cell and liver fibrogenesis","volume":"1866","author":"Chen","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.jhepr.2021.100316_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tips.2015.05.001","article-title":"Nitric oxide in liver diseases","volume":"36","author":"Iwakiri","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jhepr.2021.100316_bib16","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1073\/pnas.1922608117","article-title":"beta-Arrestin2 is a critical component of the GPCR-eNOS signalosome","volume":"117","author":"Liu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100316_bib17","article-title":"Beta-arrestin-2 is increased in chronic liver injury","author":"Schierwagen","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100316_bib18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/33934","article-title":"Dynamic activation of endothelial nitric oxide synthase by Hsp90","volume":"392","author":"Garcia-Cardena","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100316_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.02.028","article-title":"Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease","author":"Yang","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.molcel.2006.12.008","article-title":"An acetylation site in the middle domain of Hsp90 regulates chaperone function","volume":"25","author":"Scroggins","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhepr.2021.100316_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2018.10.015","article-title":"Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury","volume":"70","author":"Ruart","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jhep.2019.10.028","article-title":"A\u00a0defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis","volume":"72","author":"Hammoutene","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2016.07.051","article-title":"Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury","volume":"66","author":"Guixe-Muntet","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010016","article-title":"Relevance of autophagy in parenchymal and non-parenchymal liver cells for health and disease","volume":"8","author":"Weiskirchen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2021.100316_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1196\/annals.1396.003","article-title":"Age-related changes in the liver sinusoidal endothelium: a mechanism for dyslipidemia","volume":"1114","author":"DG","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jhepr.2021.100316_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/jhep.2001.22754","article-title":"Pseudocapillarization and associated energy limitation in the aged rat liver","volume":"33","author":"Le Couteur","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ar.20661","article-title":"Old age and the hepatic sinusoid","volume":"291","author":"Le Couteur","year":"2008","journal-title":"Anat Rec (Hoboken)"},{"key":"10.1016\/j.jhepr.2021.100316_bib28","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ar.23263","article-title":"\"The sinusoid\" in the liver: lessons learned from the original definition by Charles Sedgwick Minot (1900)","volume":"298","author":"Wake","year":"2015","journal-title":"Anat Rec (Hoboken)"},{"key":"10.1016\/j.jhepr.2021.100316_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.14336\/AD.2019.0127","article-title":"Aging influences hepatic microvascular biology and liver fibrosis in advanced chronic liver disease","volume":"10","author":"Maeso-Diaz","year":"2019","journal-title":"Aging Dis"},{"key":"10.1016\/j.jhepr.2021.100316_bib30","doi-asserted-by":"crossref","first-page":"G144","DOI":"10.1152\/ajpgi.00179.2018","article-title":"Manipulating fenestrations in young and old liver sinusoidal endothelial cells","volume":"316","author":"Hunt","year":"2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib32","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100316_bib33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bpg.2011.02.011","article-title":"Anti-fibrogenic strategies and the regression of fibrosis","volume":"25","author":"Kisseleva","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100316_bib34","doi-asserted-by":"crossref","first-page":"G110","DOI":"10.1152\/ajpgi.00412.2010","article-title":"Hepatic stellate cells require a stiff environment for myofibroblastic differentiation","volume":"301","author":"Olsen","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fphys.2015.00359","article-title":"Interplay of matrix stiffness and c-SRC in hepatic fibrosis","volume":"6","author":"Gortzen","year":"2015","journal-title":"Front Physiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib36","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00447.2014","article-title":"Novel insights into the function and dynamics of extracellular matrix in liver fibrosis","volume":"308","author":"Karsdal","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/apt.15773","article-title":"Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis","volume":"52","author":"Villesen","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2021.100316_bib38","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1096\/fj.14-268425","article-title":"Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice","volume":"30","author":"Liu","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.jhepr.2021.100316_bib39","doi-asserted-by":"crossref","first-page":"R383","DOI":"10.1016\/j.cub.2020.03.051","article-title":"Durotaxis","volume":"30","author":"Sunyer","year":"2020","journal-title":"Curr Biol"},{"key":"10.1016\/j.jhepr.2021.100316_bib40","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.aaf7119","article-title":"Collective cell durotaxis emerges from long-range intercellular force transmission","volume":"353","author":"Sunyer","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100316_bib41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2015.11.019","article-title":"Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension","volume":"64","author":"Jalan","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/liv.13243","article-title":"Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: a prospective multicentre study","volume":"37","author":"Jansen","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100316_bib43","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.27343","article-title":"Molecular pathophysiology of portal hypertension","volume":"61","author":"Fernandez","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-030-11093-2_9","article-title":"Pericytes in the liver","volume":"1122","author":"Kostallari","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jhepr.2021.100316_bib45","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1053\/jhep.2002.32524","article-title":"Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis","volume":"35","author":"Corpechot","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib46","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","article-title":"Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice","volume":"126","author":"Fernandez","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib47","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.21785","article-title":"Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats","volume":"46","author":"Fernandez","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1476-5381.2009.00158.x","article-title":"Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis","volume":"157","author":"Hennenberg","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhepr.2021.100316_bib49","doi-asserted-by":"crossref","first-page":"36220","DOI":"10.18632\/oncotarget.26333","article-title":"The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension","volume":"9","author":"Uschner","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2021.100316_bib50","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/hep.26995","article-title":"Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats","volume":"60","author":"Coch","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib51","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.068","article-title":"Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension","volume":"137","author":"Van Steenkiste","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.abb.2011.02.024","article-title":"Role of myosin light chain kinase and myosin light chain phosphatase in the resistance arterial myogenic response to intravascular pressure","volume":"510","author":"Cole","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jhepr.2021.100316_bib53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/jpet.111.179143","article-title":"Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice","volume":"337","author":"van Beuge","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jhepr.2021.100316_bib54","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s11095-011-0430-9","article-title":"Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632","volume":"28","author":"van Beuge","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.jhepr.2021.100316_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12703\/P6-95","article-title":"Future therapy of portal hypertension in liver cirrhosis - a guess","volume":"6","author":"Sauerbruch","year":"2014","journal-title":"F1000prime Rep"},{"key":"10.1016\/j.jhepr.2021.100316_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.21502","article-title":"Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins","volume":"45","author":"Hennenberg","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib57","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.23222","article-title":"Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis","volume":"50","author":"Trebicka","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib58","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.22170","article-title":"Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats","volume":"47","author":"Trebicka","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib59","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.25780","article-title":"Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents","volume":"56","author":"Kageyama","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib60","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/iub.1492","article-title":"Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR-S1PR2-dependent mechanism","volume":"68","author":"Xu","year":"2016","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jhepr.2021.100316_bib61","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gut.2010.226407","article-title":"Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction","volume":"60","author":"Moleda","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib62","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.gastro.2013.06.036","article-title":"Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis","volume":"145","author":"Grace","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138732","article-title":"Hemodynamic effects of the non-peptidic angiotensin-(1-7) agonist AVE0991 in liver cirrhosis","volume":"10","author":"Klein","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100316_bib64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev.physiol.68.040504.094707","article-title":"Signaling for contraction and relaxation in smooth muscle of the gut","volume":"68","author":"Murthy","year":"2006","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib65","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/liv.14586","article-title":"Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction","volume":"40","author":"Uschner","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100316_bib66","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1038\/s41598-018-27656-y","article-title":"The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats","volume":"8","author":"Schwabl","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100316_bib67","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.3748\/wjg.v24.i38.4356","article-title":"Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension","volume":"24","author":"Schaffner","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100316_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176223","article-title":"Phosphodiesterases in the liver as potential therapeutic targets of cirrhotic portal hypertension","volume":"21","author":"Kreisel","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2021.100316_bib69","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/hep.27049","article-title":"Novel role of nuclear receptor Rev-erbalpha in hepatic stellate cell activation: potential therapeutic target for liver injury","volume":"59","author":"Li","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12072-017-9826-x","article-title":"Biology of portal hypertension","volume":"12","author":"McConnell","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2021.100316_bib71","first-page":"1238","article-title":"Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension","volume":"21","author":"Wanless","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib72","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/0016-5085(95)90211-2","article-title":"Accumulation and cellular localization of fibrinogen\/fibrin during short-term and long-term rat liver injury","volume":"108","author":"Neubauer","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib73","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2003.032136","article-title":"A\u00a0role for thrombin in liver fibrosis","volume":"53","author":"Duplantier","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib74","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1172\/JCI18114","article-title":"The Fgl2\/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis","volume":"112","author":"Marsden","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100316_bib75","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.phrs.2004.04.009","article-title":"A\u00a0study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat","volume":"51","author":"Abdel-Salam","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jhepr.2021.100316_bib76","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10620-006-9595-1","article-title":"The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis","volume":"52","author":"Assy","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2021.100316_bib77","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2006.08.023","article-title":"Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat","volume":"46","author":"Abe","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib78","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"Cerini","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib79","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13510","article-title":"Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis","volume":"38","author":"Fortea","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100316_bib80","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant Rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib81","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/hep.27387","article-title":"Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal\u00a0thrombosis and mechanical forces","volume":"61","author":"Simonetto","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib82","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.gastro.2019.03.013","article-title":"Mechanical stretch increases expression of CXCL1 in liver sinusoidal endothelial cells to recruit neutrophils, generate sinusoidal microthombi, and promote portal hypertension","volume":"157","author":"Hilscher","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-017-9827-9","article-title":"The portal hypertension syndrome: etiology, classification, relevance, and animal models","volume":"12","author":"Bosch","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2021.100316_bib84","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF01308377","article-title":"Spontaneous portosystemic shunt: relationship to spontaneous encephalopathy and gastrointestinal hemorrhage","volume":"26","author":"Lam","year":"1981","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2021.100316_bib85","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/hep.510290436","article-title":"Increased angiogenesis in portal hypertensive rats: role of nitric oxide","volume":"29","author":"Sumanovski","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib86","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","article-title":"Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions","volume":"61","author":"Iwakiri","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib87","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2008.09.019","article-title":"Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension","volume":"50","author":"Tiani","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib88","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/hep.25625","article-title":"Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats","volume":"56","author":"Huang","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib89","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib90","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","article-title":"Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats","volume":"51","author":"Reiberger","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib91","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/hep.24238","article-title":"Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice","volume":"53","author":"Van Steenkiste","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib92","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jhep.2020.03.019","article-title":"Paneth cells promote angiogenesis and regulate portal hypertension in response to microbial signals","volume":"73","author":"Hassan","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib93","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","article-title":"Functional aspects on the pathophysiology of portal hypertension in cirrhosis","volume":"57","author":"Garcia-Pagan","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib94","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI7458","article-title":"Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility","volume":"104","author":"Wiest","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100316_bib95","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1053\/gast.2002.33586","article-title":"Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis","volume":"122","author":"Tazi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib96","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.gastro.2005.04.016","article-title":"Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling","volume":"129","author":"Tazi","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib97","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/gutjnl-2019-319044","article-title":"Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS","volume":"69","author":"Queck","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib98","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0038-1655904","article-title":"Ongoing prothrombotic state in the portal circulation of cirrhotic patients","volume":"77","author":"Violi","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jhepr.2021.100316_bib99","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-230X-11-107","article-title":"The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS)","volume":"11","author":"Benten","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100316_bib100","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1053\/j.gastro.2005.11.029","article-title":"Defective RhoA\/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats","volume":"130","author":"Hennenberg","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib101","article-title":"Activation of the alternate renin-angiotensin system correlates with the clinical status in human cirrhosis and corrects post liver transplantation","volume":"8","author":"Casey","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhepr.2021.100316_bib102","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jhep.2012.07.033","article-title":"HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects","volume":"57","author":"Klein","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib103","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41598-019-38678-5","article-title":"Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats","volume":"9","author":"Klein","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100316_bib104","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.cell.2018.02.044","article-title":"The human gut microbiome: from association to modulation","volume":"172","author":"Schmidt","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2021.100316_bib105","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1136\/gutjnl-2016-312729","article-title":"Gut microbiome and liver diseases","volume":"65","author":"Tilg","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib106","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","article-title":"Porto-sinusoidal vascular disease: proposal and description of a novel entity","volume":"4","author":"De Gottardi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib107","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib108","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.1840170622","article-title":"Bacterial translocation in acute and chronic portal hypertension","volume":"17","author":"Garcia-Tsao","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib109","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/0016-5085(95)90147-7","article-title":"Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites","volume":"108","author":"Garcia-Tsao","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib110","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jhep.2019.06.017","article-title":"FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis","volume":"71","author":"Sorribas","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib111","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/apt.15365","article-title":"Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90-day mortality","volume":"50","author":"Jansen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2021.100316_bib112","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib113","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A\u00a0human gut microbial gene catalogue established by metagenomic sequencing","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100316_bib115","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","article-title":"Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis","volume":"72","author":"Bajaj","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib116","article-title":"Targeting the gut-liver-immune axis to treat cirrhosis","author":"Tranah","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib117","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib118","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","article-title":"The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats","volume":"185","author":"Verbeke","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2021.100316_bib119","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100316_bib120","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2015.12.010","article-title":"Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats","volume":"64","author":"Ubeda","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib121","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hep.30349","article-title":"Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis","volume":"70","author":"Munoz","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/lt.25882","article-title":"Variation in bile microbiome by the etiology of cholestatic liver disease","author":"Tyc","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2021.100316_bib123","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/gutjnl-2018-316227","article-title":"Circulating microbiome in blood of different circulatory compartments","volume":"68","author":"Schierwagen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib124","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2019.00069","article-title":"Compartmentalization of immune response and microbial translocation in decompensated cirrhosis","volume":"10","author":"Alvarez-Silva","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2021.100316_bib125","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/hep.29612","article-title":"Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality","volume":"67","author":"Jansen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib126","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis","volume":"40","author":"Czaja","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib127","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100316_bib128","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib129","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","article-title":"The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology","volume":"73","author":"Trebicka","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.03.026","article-title":"Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis","author":"Martinez","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib131","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","article-title":"The clinical use of HVPG measurements in chronic liver disease","volume":"6","author":"Bosch","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib132","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jhep.2013.06.014","article-title":"TIPS: 25 years later","volume":"59","author":"Rossle","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib133","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0016-5107(03)02544-6","article-title":"EUS-guided portal vein catheterization and pressure measurement in an animal model: a pilot study of feasibility","volume":"59","author":"Lai","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhepr.2021.100316_bib134","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.gie.2016.09.026","article-title":"EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study","volume":"85","author":"Huang","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhepr.2021.100316_bib135","doi-asserted-by":"crossref","first-page":"G584","DOI":"10.1152\/ajpgi.00135.2020","article-title":"Endoscopic ultrasound-guided sampling and profiling of portal circulation in human patients for metabolic research studies and biomarker assessment","volume":"319","author":"Ryou","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib136","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","article-title":"Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis","volume":"144","author":"Berzigotti","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib137","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib138","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/gutjnl-2016-311536","article-title":"Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study","volume":"65","author":"Jansen","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib139","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/liv.14439","article-title":"2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: an individual patient data meta-analysis","volume":"40","author":"Thiele","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100316_bib140","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jhep.2015.10.009","article-title":"Multiparametric magnetic resonance imaging predicts clinical outcomes\u00a0in patients with chronic liver disease","volume":"64","author":"Pavlides","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib141","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1148\/radiol.2018180051","article-title":"Quantification of liver fibrosis at T1 and T2 mapping with extracellular volume fraction MRI: preclinical results","volume":"288","author":"Luetkens","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2021.100316_bib142","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/gutjnl-2017-314561","article-title":"Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study","volume":"67","author":"Luetkens","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib143","article-title":"Magnetic resonance parametric mapping of the spleen for non-invasive assessment of portal hypertension","author":"Mesropyan","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib144","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3109\/00365521.2014.996590","article-title":"Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis","volume":"50","author":"Leeming","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100316_bib145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108544","article-title":"PRO-C3-levels in patients with HIV\/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension","volume":"9","author":"Jansen","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100316_bib146","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/hep4.1135","article-title":"Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis","volume":"2","author":"Praktiknjo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2021.100316_bib147","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/MEG.0b013e32834a75dc","article-title":"Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt","volume":"23","author":"Trebicka","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083341","article-title":"Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension","volume":"8","author":"Trebicka","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100316_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2019-320170","article-title":"Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation","author":"Monteiro","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib150","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/liv.14433","article-title":"Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure","volume":"40","author":"Praktiknjo","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100316_bib151","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2012.10.015","article-title":"Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis","volume":"58","author":"Trebicka","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103779","article-title":"The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS","volume":"9","author":"Jansen","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100316_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116768","article-title":"Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV\/HCV coinfection","volume":"10","author":"Jansen","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100316_bib154","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension","volume":"69","author":"Abraldes","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","article-title":"Propranolol--a medical treatment for portal hypertension?","volume":"2","author":"Lebrec","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100316_bib156","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/hep.1840020502","article-title":"The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study","volume":"2","author":"Lebrec","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib157","article-title":"Multicenter randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed","volume":"46","author":"Tripathi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib158","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.23045","article-title":"Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed","volume":"50","author":"Tripathi","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib159","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib160","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100316_bib161","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100316_bib162","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/gutjnl-2011-301348","article-title":"The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease","volume":"61","author":"Krag","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib163","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2016.10.025","article-title":"Emergency TIPS in a Child-Pugh B patient: when does the window of opportunity open and close?","volume":"66","author":"Trebicka","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib164","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib165","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nrgastro.2012.96","article-title":"Recent advances in our understanding of hepatorenal syndrome","volume":"9","author":"Wong","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib166","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib167","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM199401203300303","article-title":"The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding","volume":"330","author":"Rossle","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100316_bib168","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.47.2.288","article-title":"Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study","volume":"47","author":"Brensing","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib169","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jgh.12725","article-title":"Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion","volume":"30","author":"Tan","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0038-1627457","article-title":"Does transjugular intrahepatic portosystemic shunt stent differentially improve survival in a subset of cirrhotic patients?","volume":"38","author":"Trebicka","year":"2018","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2021.100316_bib171","doi-asserted-by":"crossref","first-page":"8897","DOI":"10.1073\/pnas.151136298","article-title":"NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension","volume":"98","author":"Fiorucci","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100316_bib172","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ajg.2009.661","article-title":"NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study","volume":"105","author":"Berzigotti","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100316_bib173","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib174","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.28898","article-title":"Rifaximin has no effect on hemodynamics in decompensated cirrhosis: a randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kimer","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib175","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00109-018-1642-9","article-title":"Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation","volume":"96","author":"Eguchi","year":"2018","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.jhepr.2021.100316_bib176","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep4.1360","article-title":"Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-mediated paracrine mechanism","volume":"3","author":"Gracia-Sancho","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2021.100316_bib177","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/hep.30199","article-title":"Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension","volume":"69","author":"Garcia-Tsao","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib178","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib179","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib180","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib181","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib182","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2021.100316_bib183","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib184","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib185","doi-asserted-by":"crossref","first-page":"40461","DOI":"10.1038\/srep40461","article-title":"A\u00a0nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats","volume":"7","author":"Rodriguez","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100316_bib186","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(14)60004-0","article-title":"Obeticholic acid, a Farnesoid-X Receptor-agonist, reduces bacterial translocation and restores intestinal permeability in a rat model of cholestatic liver disease","volume":"60","author":"Verbeke","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib187","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib188","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/jgh.14700","article-title":"Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension","volume":"34","author":"Semmler","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib189","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib190","article-title":"Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation","author":"Serper","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib191","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/hep.26627","article-title":"Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in\u00a0vivo","volume":"59","author":"Fallowfield","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib192","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002248","article-title":"Serelaxin as a potential treatment for renal dysfunction in cirrhosis: preclinical evaluation and results of a randomized phase 2 trial","volume":"14","author":"Snowdon","year":"2017","journal-title":"PloS Med"},{"key":"10.1016\/j.jhepr.2021.100316_bib193","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s13063-020-4203-9","article-title":"A\u00a0phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)","volume":"21","author":"Gifford","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.jhepr.2021.100316_bib194","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodriguez-Vilarrupla","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib195","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.01.025","article-title":"Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats","volume":"60","author":"Schwabl","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib196","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2018.03.018","article-title":"Beneficial effects of the peroxisome proliferator-activated receptor alpha\/gamma agonist aleglitazar on progressive hepatic and splanchnic abnormalities in cirrhotic rats with portal hypertension","volume":"188","author":"Tsai","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2021.100316_bib197","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00127.2009","article-title":"Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats","volume":"297","author":"Kemp","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2021.100316_bib198","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11684-019-0689-5","article-title":"Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats","volume":"13","author":"Zhang","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.jhepr.2021.100316_bib199","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.27117","article-title":"Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis","volume":"60","author":"Granzow","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100316_bib200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/gutjnl-2015-309600","article-title":"Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis","volume":"66","author":"Klein","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100316_bib201","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.dld.2014.12.017","article-title":"Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats","volume":"47","author":"Wang","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2021.100316_bib202","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/jgh.13207","article-title":"Combined administration of propranolol\u00a0+ AG490 offers better effects on portal hypertensive rats with cirrhosis","volume":"31","author":"Wang","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100316_bib203","doi-asserted-by":"crossref","first-page":"11598","DOI":"10.1038\/s41598-019-48024-4","article-title":"TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor","volume":"9","author":"Klein","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100316_bib204","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1053\/j.gastro.2016.08.059","article-title":"Ruxolitinib for the treatment of portal hypertension in a patient with primary myelofibrosis","volume":"157","author":"Tan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100316_bib205","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/003655202320378284","article-title":"Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic portosystemic stent-shunt","volume":"37","author":"Brensing","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100316_bib206","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1476-5381.2012.02074.x","article-title":"Portal hypertension and liver cirrhosis in rats: effect of the beta3-adrenoceptor agonist SR58611A","volume":"167","author":"Vasina","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhepr.2021.100316_bib207","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2105-10-48","article-title":"GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists","volume":"10","author":"Eden","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jhepr.2021.100316_bib208","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021800","article-title":"REVIGO summarizes and visualizes long lists of gene ontology terms","volume":"6","author":"Supek","year":"2011","journal-title":"PloS One"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:26:34Z","timestamp":1762899994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921000926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":208,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2589555921000926"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100316","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100316"}}